16th AD/PD™ 2022 is the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. The groundbreaking series of Alzheimer’s and Parkinson’s Diseases Conferences attract international medical and scientific professionals worldwide. Moreover, the conference is at the forefront of unravelling the mechanisms. In addition, it advocates improving the treatment of Alzheimer’s, Parkinson’s, and other related neurodegenerative diseases. AD/PD™ Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention, and therapy.
Improving Treatment of Neurological Disorders
For the first time this year in 2022, by merging with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now an annual meeting. Continuing its focus on the Advances in Science & Therapy of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
AD/PD™ 2022 is the 16th edition of the AD/PD™ Conference. This hybrid event will be held in Barcelona, Spain and online from 15-20 March 2022. The lecturers and speakers will deliver the conference in English for an excellent understanding at a global standard. AD/PD™ Conference expects 2,500 participants in person and 1,100 online.
Ideology of AD/PD™ 2022
16th AD/PD™ 2022 revolves around the ideology of providing a better future for patients suffering from neurodegenerative diseases. The misery for patients and families associated with neurodegenerative diseases is a driving force for the organisers. And for the collaborators to advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers. Under the firm’s motto of delivering an improved lifestyle to individuals affected by neurodegenerative diseases, the AD/PD™ conference offers the finest scientific program covering the most recent research, clinical trials, developments, and treatments in Alzheimer’s and Parkinson’s. Furthermore, participants will receive unparalleled and powerful insights into distinct neurodegenerative diseases in one setting to examine their similarities and differences.
16th AD/PD™ 2022 welcomes clinicians and researchers working in Alzheimer’s, Parkinson’s and related neurodegenerative diseases. The primary speciality of their audience is neurosciences for the research segment and neurology for the clinical segment. Secondary specialities include biochemistry, molecular cell biology, pharmacology, psychiatry, and geriatrics.
Invitation to International Medical and Scientific Professionals
16th AD/PD™ 2022 provides exceptional opportunities for international medical and scientific professionals to come together and discuss the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
16th AD/PD™ 2022 will primarily focus on advancing research and presenting the latest findings, improving the treatment of Alzheimer’s, Parkinson’s, and other related neurodegenerative diseases and lastly, a strong focus is the mechanisms of the diseases, prevention, and therapy.
The reason for the success of the AD/PD™ Conferences is their academic quality combined with the interactive and collegial environment. They believe that there is no other conference in the world that presents such a high level of science in a condensed manner on one hand, yet on the other hand, provides an enormously comfortable atmosphere in which to enjoy it all.
